ArticleCureus2025
A Case of Laxative-Induced Severe Hypermagnesemia in a Peritoneal Dialysis Patient.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 55-year-old man undergoing peritoneal dialysis (PD) was transferred from a rehabilitation facility to our hospital due to altered consciousness and respiratory distress. Upon arrival, he presented with a Glasgow Coma Scale score of E3V5M6 and hypercapnia with a pCO₂ of 54.6 mmHg. His reduced urine output raised concerns for uremia secondary to diminished residual renal function, prompting the urgent initiation of hemodialysis. However, subsequent investigations revealed that he had been taking magnesium oxide (1980 mg/day) as a laxative and that his serum magnesium level was markedly elevated at 8.4 mg/dL, consistent with hypermagnesemia. Magnesium toxicity, impaired consciousness, and hypercapnia improved after hemodialysis and the cessation of magnesium oxide. The patient was ultimately switched back to PD without recurrence of hypermagnesemia and was discharged. It is important to note that magnesium clearance in patients undergoing PD relies primarily on residual renal function; thus, in patients with diminished residual renal function, the use of magnesium-containing laxatives may precipitate severe hypermagnesemia. Careful consideration is warranted when prescribing magnesium-containing laxatives in patients with diminished residual renal function, even those undergoing PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.